The head of global clinical development for immunology/bone at UCB talked about findings presented at CTAD 2024 from the phase 2 trial assessing bepranemab in Alzheimer disease. [WATCH TIME: 3 minutes]
Matthew Barton, PhD
Advertisement
Head of global clinical development for immunology/bone at UCB.
Articles by Matthew Barton, PhD
Advertisement
Latest Updated Articles
Assessing Phase 2 Data on Bepranemab’s Effect on Tau Accumulation and Cognitive Function: Matthew Barton, PhDPublished: November 7th 2024 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
How Multiple Sclerosis Affects Men
2
This Week on NeurologyLive® — October 13, 2025
3
Reflecting on Contributions to Child Neurology at 2025 CNS Annual Meeting: Brenda Banwell, MD, FRCPC, FAAN
4
ECTRIMS Congress 2025: Top Expert Interviews and Key Takeaways
5
